Prosecution Insights
Last updated: April 19, 2026
Application No. 18/456,515

PROSTHETIC HEART VALVE TISSUE DURABILITY STRUCTURE AND METHOD

Non-Final OA §102§103§112
Filed
Aug 27, 2023
Examiner
BARIA, DINAH N
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Medtronic Vascular, Inc.
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
2y 9m
To Grant
99%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allow Rate
456 granted / 622 resolved
+3.3% vs TC avg
Strong +29% interview lift
Without
With
+29.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
50 currently pending
Career history
672
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
34.9%
-5.1% vs TC avg
§102
21.3%
-18.7% vs TC avg
§112
30.8%
-9.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 622 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement Applicant should note that the large number of references in the attached IDS have been considered by the examiner in the same manner as other documents in Office search files are considered by the examiner while conducting a search of the prior art in a proper field of search. See MPEP 609.05(b). Applicant is requested to point out any specific references in the IDS which they believe may be of particular relevance to the instant claimed invention in response to this office action. Drawings The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the valve prosthesis comprising valve leaflets, a valve inflow cylinder proximal the valve leaflets, first support stitching circumferentially around the inflow cylinder, second support stitching circumferentially around the inflow cylinder and longitudinally spaced from the first support stitching, a circumferential space between the first and second support stitching, and a stent structure coupled to the circumferential space by margin of attachment stitching (claim 15) must be shown or the feature(s) canceled from the claim(s). No new matter should be entered. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 9, 15 and 18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 9, it is unclear what, if any, additional structural limitations are imparted on the final structure of the claimed device by the parameter set forth in this claim. Specifically, the parameter set forth in this claim merely seems to be reciting a function of the first supporting stitching, however does not include, or suggest, any additional structure which would be needed in order to meet this function/parameter. Thus, one having ordinary skill in the art would not reasonable be apprised of the scope of the invention, thereby rendering the claim indefinite. Regarding claim 15, which sets forth the parameter of “margin of attachment (MOA) stitching coupling the circumferential space to the stent structure”; however, this parameter is found to be confusing since it is not clear what exactly, structurally, is meant by the term “margin of attachment (MOA) stitching”. Specifically, it is not clear what exact structure/pattern would be needed in order to meet the claimed parameter of having margin of attachment (MOA) stitching coupling the stent structure of the circumferential space; and the originally filed disclosure does not aid in clarifying what structure/pattern a “margin of attachment (MOA) stitching” would be. Thus, one having ordinary skill in the art would not reasonable be apprised of the scope of the invention, thereby rendering the claim indefinite. Regarding claim 18, which sets forth the parameter of “the inner skirt comprising inner skirt cells matching the inflow portion cells” (emphasis added); however, this parameter is found to be confusing since it is not clear what exactly, structurally, is meant by the term “inner skirt cells”. Specifically, are inner skirt cells cellular agents/products in/on the inner skirt, or are they openings/windows in the inner skirt, or are they something else completely different. Thus, one having ordinary skill in the art would not reasonable be apprised of the scope of the invention, thereby rendering the claim indefinite. Examiner’s Notes It is to be noted that in device/apparatus claims only the claimed structure of the final device bears patentable weight, and intended use/functional language is considered to the extent that it further defines the claimed structure of the final device (see MPEP 2114). Examiner cites particular columns and line numbers in the references as applied to the claims below for the convenience of the applicant(s). Although the specified citations are representative of the teachings in the art and are applied to the specific limitations within the individual claim, other passages and figures may apply as well. It is respectfully requested that, in preparing responses, the applicant(s) fully consider the references in entirety as potentially teaching all or part of the claimed invention, as well as the context of the passage as taught by the prior art or disclosed by the examiner. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 5 and 6 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Schwartz et al. (WO 2019/144036), as disclosed in the IDS dated 06/23/2024, hereinafter Schwartz. Regarding claims 5 and 6, Schwartz discloses a valve prosthesis (600), illustrated in Figures 32-36, comprising a stent structure (602); a prosthetic valve (612) coupled to the stent structure, wherein the stent structure (602) comprises an outflow portion (610) comprising an outflow portion crown ring comprising superior crowns (606) coupled to outflow portion struts (604); and a superior tissue bumper (616) covering the superior crowns (606) and the outflow portion struts (604), illustrated in Figures 32-36 ([0160] & [0162], Lines 3-5). Claims 8-10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Duran et al. (US PG Pub. 2004/0215333), hereinafter Duran. Regarding claims 8-10, Duran discloses a valve prosthesis comprising a prosthetic valve (15) comprising valve leaflets (3); a valve inflow cylinder (IC) proximal of the valve leaflets (3); and a first support stitching (17) extending in a circumferential direction around the valve inflow cylinder (IC), the first support stitching (17) being less elastic than, and supporting, the valve inflow cylinder/pericardium, and the first support stitching (17) extending in and out of the valve inflow cylinder from an outer surface of the valve inflow cylinder to an inner surface of the valve inflow cylinder through the valve inflow cylinder, illustrated in Figures 4-6 and modified figure 6, below ([0063] – [0065]). PNG media_image1.png 404 407 media_image1.png Greyscale Claims 16 and 20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Mathison (US Patent No. 7,998,196). Regarding claims 16 and 20, Mathison teaches a valve prosthesis comprising an integral prosthetic valve (100’) comprising a cylindrical inflow end (104’); valve leaflets (outlined by cusps 108a-c); a valve inflow cylinder (a layer in the portion from 104’ to 107) extending distally from the cylindrical inflow end to the valve leaflets; and an inner skirt (the other layer extending from 104’ to 102’) extending distally from the cylindrical inflow end and overlapping the valve leaflets, illustrated in Figures 1D1 and 1E (Column 8, Lines 37-65). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-4 are rejected under 35 U.S.C. 102(a)(1) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Braido et al. (US PG Pub. 2015/0289973), as disclosed in the IDS dated 06/23/2024, hereinafter Braido. Regarding claims 1-4, Braido discloses a valve prosthesis (800), illustrated in Figure 8, comprising a stent structure (802); a prosthetic valve/leaflets coupled to the stent structure, wherein the stent structure (802) comprises an inflow portion (IP) comprising an outflow crown ring (CR) comprising outflow struts (803), outflow crowns (OC) coupled to the outflow struts (803), and central crowns (CC); and an inferior tissue bumper (850) covers the outflow crowns (OC), the outflow struts (803), and the central crowns (CC), wherein the inferior tissue bumper prevents the prosthetic valve/leaflets from contacting the outflow crowns, illustrated in Figure 8 and modified figure 8, below ([0038] & [0039] – to clarify, it is stated that the tissue bumper/buffer strip 850 can include at tops, and/or bottoms, of a full row of cells 812; thereby teaching and/or being obvious to one having ordinary skill in the art before the effective filing date of the invention for the tissue bumper/buffer strip 850 to cover the outflow struts, outflow crowns, and central crowns, of the outflow crown ring CR of the inflow portion IP, of the valve prosthesis, as claimed). PNG media_image2.png 542 891 media_image2.png Greyscale Claim 7 is rejected under 35 U.S.C. 103 as being unpatentable over Schwartz as applied to claim 5 above, and further in view of Ben Zaken et al. (WO 2022/076508), as disclosed in the IDS dated 06/23/2024, hereinafter Ben Zaken. Regarding claim 7, Schwartz discloses the valve prosthesis of claim 5, wherein the outflow portion (610) further comprises non-commissure posts, illustrated in Figures 33-36; but does not specifically disclose the superior tissue bumper further covering the non-commissure posts. However, Ben Zaken teaches a valve prosthesis, in the same field of endeavor, comprising non-commissure posts covered with a tissue bumper/pad (170b), illustrated in Figures 19 and 20; the tissue bumper/pad configured to be placed at any location/struts that would contact leaflets, in order to protect the leaflets from damage as they open against the frame/stent ([0592], Last 2 Lines & [0604]). In view of the teachings of Ben Zaken, it would have been obvious to one having ordinary skill in the art before the effective filing date of the invention for the non-commissure posts, of the valve prosthesis of Schwartz, to further be covered by the superior tissue bumper, in order to protect valve leaflets from damage as they open against the stent, as taught by Ben Zaken. Claims 11-14 are rejected under 35 U.S.C. 103 as being unpatentable over Duran. Regarding claims 11-14, Duran discloses the valve prosthesis of claim 8, wherein the support stitching (17) comprises sutures ([0064], Lines 10-14); and though it is not specifically disclosed that a second support stitching, less elastic than the valve inflow cylinder, extends in the circumferential direction around the valve inflow cylinder, longitudinally spaced from the first support stitching, such that there is a circumferential space defined between the first and second support stitching, this parameter is deemed to be a mere matter of normal design choice, not involving a novel, inventive step. It would have been obvious, and well within the capability of one having ordinary skill in the art before the effective filing date of the invention to determine an appropriate amount of supports stitching to have in the inflow cylinder, including a second support stitching longitudinally spaced from the first support stitching such that there is a circumferential space between the two, since doing so amounts to mere duplication of the essential working parts, i.e. support stitching, which has been held to involve only routine skill in the art (see MPEP 2144.04). Claims 16 and 17 are rejected under 35 U.S.C. 103 as being unpatentable over Alon et al. (US Patent No. 8,652,202), hereinafter Alon. Regarding claims 16 and 17, Alon discloses a valve prosthesis (10), illustrated in Figures 6 and 7, comprising a prosthetic valve (14) comprising a cylindrical inflow end (44); valve leaflets (34a-c); a valve inflow cylinder (IFC) extending distally from the cylindrical inflow end (44) to the valve leaflets; an inner skirt (42) extending distally from the cylindrical inflow end (44), and a stent structure (20) coupled to the prosthetic valve, the inner skirt (42) being between the valve inflow cylinder (IFC) and the stent structure (12), illustrated in Figures 6, 7 and modified figure 6, below (Column 10, Lines 5-22); and though it is not specifically disclosed the prosthetic valve is integral, the term “integral” is considered to be sufficiently broad to embrace constructions united by different means such as fastening, suturing etc., and it would have been obvious to one having ordinary skill in the art before the effective filing date of the invention to have the prosthetic valve, of the valve prosthesis of Along, be integral, since it has been held that forming in one piece an article which has formerly been formed in two pieces and put together involves only routine skill in the art (see MPEP 2144.04). PNG media_image3.png 434 435 media_image3.png Greyscale Claims 16 and 19 are rejected under 35 U.S.C. 103 as being unpatentable over Braido et al. (US PG Pub. 2015/0209136), hereinafter Braido’136. Regarding claims 16 and 19, Braido’136 discloses a valve prosthesis (1000), illustrated in Figures 10A and 10B, comprising a prosthetic valve/valve assembly (1008) comprising a cylindrical inflow end (1011); valve leaflets (1010); a valve inflow cylinder (1012), extending distally from the cylindrical inflow end (1011) to the valve leaflets (1010); an inner skirt (1020), extending distally from the cylindrical inflow end (1011); and cusps (C) between the valve leaflets (1010) and the valve inflow cylinder (1012), wherein the inner skirt (1020) extends distally to a cylindrical outflow end (1052) proximal of the cusps (C), illustrated in Figures 10A, 10B and modified figure 10A, below ([0139]; [0140] & [0142]); and though it is not specifically disclosed the prosthetic valve/valve assembly (1008) is integral, the term “integral” is considered to be sufficiently broad to embrace constructions united by different means such as fastening, suturing etc., and it would have been obvious to one having ordinary skill in the art before the effective filing date of the invention to have the prosthetic valve/valve assembly, of the valve prosthesis of Braido‘136, be integral, since it has been held that forming in one piece an article which has formerly been formed in two pieces and put together involves only routine skill in the art (see MPEP 2144.04). PNG media_image4.png 649 755 media_image4.png Greyscale Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DINAH BARIA whose telephone number is (571)270-1973. The examiner can normally be reached Monday - Friday 10am - 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jerrah Edwards can be reached at 408-918-7557. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DINAH BARIA/Primary Examiner, Art Unit 3774 03/05/2026
Read full office action

Prosecution Timeline

Aug 27, 2023
Application Filed
Mar 05, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599700
SYSTEM AND METHODS FOR CONNECTIVE TISSUE REPAIR USING SCAFFOLDS
2y 5m to grant Granted Apr 14, 2026
Patent 12599492
AXIALLY COMPRESSIBLE BARE STENT
2y 5m to grant Granted Apr 14, 2026
Patent 12588909
TRANSCATHETER DEVICE AND MINIMALLY INVASIVE METHOD FOR CONSTRICTING AND ADJUSTING BLOOD FLOW THROUGH A BLOOD VESSEL
2y 5m to grant Granted Mar 31, 2026
Patent 12582537
STENT WITH IMPROVED DEPLOYMENT CHARACTERISTICS
2y 5m to grant Granted Mar 24, 2026
Patent 12582531
HUMERAL AND GLENOID ARTICULAR SURFACE IMPLANT SYSTEMS AND METHODS
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
99%
With Interview (+29.1%)
2y 9m
Median Time to Grant
Low
PTA Risk
Based on 622 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month